Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being

The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological... 5α-Reductase inhibitors (5α-RIs) such as finasteride and dutasteride have proven useful in clinical management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and also in treatment of androgenetic alopecia (AGA). However, these drugs have serious and, in some patients, persistent or irreversible sexual side effects. These agents interfere with the biosynthesis and metabolism of neurosteroids and may adversely affect mood, stress, and anxiety and potentiate the onset of depression. Data from preclinical and clinical studies have provided substantial evidence that these agents cause loss or reduction of libido, increase the risk of erectile dysfunction and ejaculatory dysfunction, and may contribute to the onset of depression. It is imperative that clinicians give serious considerations to these adverse effects and their impact on patients’ health and engage their patients in an open and honest discussion regarding the potential harm of these agents prior to prescribing them. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Sexual Health Reports Springer Journals

The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being

Current Sexual Health Reports , Volume 7 (4) – Aug 26, 2015

Loading next page...
 
/lp/springer-journals/the-impact-of-the-5-reductase-inhibitors-5-ris-on-male-sexual-function-SHwMxD1W0i

References (144)

Publisher
Springer Journals
Copyright
Copyright © 2015 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Urology; Endocrinology
ISSN
1548-3584
eISSN
1548-3592
DOI
10.1007/s11930-015-0061-y
Publisher site
See Article on Publisher Site

Abstract

5α-Reductase inhibitors (5α-RIs) such as finasteride and dutasteride have proven useful in clinical management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and also in treatment of androgenetic alopecia (AGA). However, these drugs have serious and, in some patients, persistent or irreversible sexual side effects. These agents interfere with the biosynthesis and metabolism of neurosteroids and may adversely affect mood, stress, and anxiety and potentiate the onset of depression. Data from preclinical and clinical studies have provided substantial evidence that these agents cause loss or reduction of libido, increase the risk of erectile dysfunction and ejaculatory dysfunction, and may contribute to the onset of depression. It is imperative that clinicians give serious considerations to these adverse effects and their impact on patients’ health and engage their patients in an open and honest discussion regarding the potential harm of these agents prior to prescribing them.

Journal

Current Sexual Health ReportsSpringer Journals

Published: Aug 26, 2015

There are no references for this article.